Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The January Application NUtritional Study (JANUS) (JANUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03604250
Recruitment Status : Recruiting
First Posted : July 27, 2018
Last Update Posted : December 3, 2018
Sponsor:
Information provided by (Responsible Party):
January, Inc.

Brief Summary:
Human beings react differently to changes in diet, exercise, and sleep patterns. The goal of this study is to (1) learn how individuals react to lifestyle choices and suggestions by examining a small group of people with similar health and lifestyle profiles; and (2) to develop algorithmic policies (male/female) that will help people optimize their health through lifestyle interventions and supplementation with prebiotics.

Condition or disease Intervention/treatment Phase
Metabolic Syndrome Dietary Supplement: Lifestyle plus prebiotic supplement Not Applicable

Detailed Description:

Human beings react differently to changes in diet, exercise, and sleep patterns. The goal of this study is two-fold and consists of two phases involving the same subjects. In the first phase, the study aims to learn how individuals react to lifestyle choices and suggestions by examining a small group of people with similar health and lifestyle profiles. Specifically, how their food choices, physical activity pattern, sleep pattern, and stress levels affect glucose metabolism, stress response, inflammation, and microbiome composition.

In the second phase of the study, the investigator's goal is to use the data collected to develop algorithmic policies that will help people optimize their health through lifestyle interventions and supplementation with prebiotics. The ultimate goal is to achieve optimization of glucose and stress regulation, inflammation state, and microbiome composition by observing real-time variations of these regulatory systems through the use of wearable health-monitoring devices and providing lifestyle suggestions via a mobile application.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 14 participants
Intervention Model: Single Group Assignment
Intervention Model Description: This is a pilot trial with a single group of 14 participants: 10 with prediabetes or at least 2 of the metabolic syndrome criteria (half males, half females) 4 healthy people (do not have prediabetes nor any of the metabolic syndrome criteria) of 11 weeks (77 days) duration.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: The January Application NUtritional Study: Health Optimization by Wearable Devices - a Pilot Trial
Estimated Study Start Date : February 2019
Estimated Primary Completion Date : May 2019
Estimated Study Completion Date : May 2019

Arm Intervention/treatment
Experimental: Lifestyle plus prebiotics
Research participants will be asked to wear health monitoring devices, including a continuous glucose monitoring device and an Apple watch. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
Dietary Supplement: Lifestyle plus prebiotic supplement
Research participants will be asked to wear health monitoring devices, including a continuous glucose and heart-rate monitors. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.




Primary Outcome Measures :
  1. Total Health Score (THS) [ Time Frame: 11 weeks ]

    The primary outcome of the study is the calculation of a Total Health Score (THS) which will include scores of body composition, glucose and stress regulation, inflammation state, and microbiome composition, based on the following data:

    • Anthropometrics
    • Blood pressure
    • Heart Rate
    • Glucose
    • Hemoglobin A1c
    • Metabolic panel
    • Complete Blood Count
    • Glomerular Filtration Rate
    • Inflammatory markers
    • Serum lipids
    • Thyroid-stimulating hormone
    • Blood ketones
    • Cortisol
    • C-peptides
    • Metagenomics
    • Metabolomics
    • 16S rRNA sequencing
    • Human genome assays (SNP, Exome+)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Gender: Both women and men
  • Age: between 30 and 60 years
  • Ethnicity and race: All
  • Are prediabetic (HbA1c </= 6.4 in the past 3 months), or have a fasting plasma glucose > 110 mg/dL, or have 2 of the metabolic syndrome criteria as defined by the International Diabetes Federation (IDF):

Central obesity, defined as waist circumference >/ = 94 cm for men and >/= 80 cm for women, or a BMI > 30 kg/m2 plus any two of the following four factors:

  • Raised triglycerides: >/= 150 mg/dL or specific treatment for this lipid abnormality
  • Reduced HDL cholesterol:
  • Men: < 40 mg/dL
  • Women: < 50 mg/dL
  • Raised blood pressure (BP): systolic BP >/= 130 mmHg or diastolic BP >/= 85 mmHg, or treatment of previously diagnosed hypertension
  • Raised fasting plasma glucose (FPG): FPG >/= 100 mg/dL

    • Have elevated levels of at least one of the following inflammatory markers: C-Reactive Protein (CRP), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Interferon gamma (IFN-G), Interleukins (IL-1b, IL-2, IL-6, IL-8, IL-10, IL-12p70), and Tumor necrosis factor alpha (TNF-a).
    • Are able to utilize a smart-phone and own an Android (v18+) or Apple phone (i0S9+)
    • Are willing to being tracked, provide multiple samples and wear a glucose monitor and a smartwatch 24 hours/day for 77 days
    • Are willing to perform finger-stick blood draws
    • Are willing to limit swimming to a maximum of 30 minutes per session during the trial
    • Are willing to limit traveling to the weekend days
    • Live in the vicinity of January Inc office and/or MBC Biolabs (Approximately 25 mile radius)
    • Are available for two, 2-4-hour meetings (study orientation and study close-out)
    • Eat a steady, consistent diet on a daily basis (see dietary exclusions below)
    • Are able to run for the time required to establish VO2 max (3-20 minutes).
    • Have the ability and willingness to give written informed consent

Exclusion Criteria:

  • Smokers
  • BMI =/> 40
  • Actively losing weight
  • Unstable diet (defined as having made any major changes to usual diet such as eliminating or significantly increasing a major food group)
  • Use of the following medications:

    • Blood thinners (i.e. warfarin/Coumadin, clopidogrel/Plavix)
    • Daily oral corticosteroids
    • Hypoglycemic medication (i.e. Precose, Metformin, Avandia, Victoza)
    • Weight loss medication
    • Digoxin/Lanoxin
    • Lithium/Lithobid
    • Theophylline/Theo 24
  • Use of the following supplements, unless they agree to discontinue starting 30 days prior to the trial: any nutritional supplements containing antioxidants (examples: multi-vitamins, antioxidant combinations, or any supplement containing vitamin C, vitamin E, beta-carotene or other carotenoids, or selenium), and fish oil/cod liver oil, flaxseed oil, and supplements containing Conjugated linoleic acid (CLA)/Gamma-linolenic acid (GLA) or turmeric.
  • Use of antibiotics, antifungals/antiparasitics in the last 30 days
  • Use of probiotic or prebiotic supplements in the last 30 days
  • People allergic to: adhesives and/or prebiotics used in the trial
  • Pregnant, lactating, have given birth in the past 6 months, or are planning to get pregnant in the next 4 months
  • Self-reported health conditions:

    • Diabetes (T1D or T2D)
    • Inflammatory Bowel Disease (Crohn's, Ulcerative Colitis)
    • Gastroenteritis, colitis or gastritis
    • Active, uncontrolled Clostridium difficile infection or H. pylori (untreated)
    • Recent heart attack (past 6 months), history of arrhythmias or cerebrovascular disease
    • Undergoing treatment for, or underwent treatment for cancer in the past 6 months
    • Esophageal, stomach colon or pancreatic cancer
    • Liver disease, other than fatty liver disease
    • Immunosuppression or immunodeficiency
    • Positive test for HIV, Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV)
    • Musculoskeletal disorder that would preclude you from performing moderate physical activity
    • LDL cholesterol =/> 190 mg/dL
    • Triglycerides (TG) =/> 450 mg/dL
    • Adrenalectomy
    • Pituitary tumor
    • Hypothalamic disease
    • Stage 3 kidney disease or worse
    • Celiac disease confirmed by blood test or biopsy
    • Insulinoma
    • Cushing's disease
    • Hyperthyroidism
    • Acromegaly
    • Pheochromocytoma
    • Addison's disease
    • Galactosemia
    • Glycogen storage disease
    • Hereditary fructose intolerance
    • Psychotic disorders or bipolar disorders
    • Current eating disorder
  • History of bariatric surgery, gallbladder removal, small bowel resection, or extensive bowel resection
  • Hospitalization for depression in past 6 months
  • Self-reported alcohol or substance abuse within the past 12 months
  • Current consumption of more than 14 alcoholic drinks per week, and/or current acute treatment or rehabilitation program for these problems
  • Self-reported inability to walk two blocks
  • Restrictive diets (i.e. vegetarians, vegans, or very restrictive diets, i.e. Paleo, Atkins, Ornish or ketogenic diets)
  • Planned travel (outside of weekends) over the course of the study (77 days) (weekend travel is ok)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03604250


Contacts
Layout table for location contacts
Contact: Antonella Dewell, MS, RD 650-485-1611 janusinfo@january.ai
Contact: Dalia Perelman, MS, RD, CDE 650-569-0462 janusinfo@january.ai

Locations
Layout table for location information
United States, California
January, Inc. Recruiting
Menlo Park, California, United States, 94025
Contact: Samuel A. Smits, PhD    408-540-4103    sam@january.ai   
Principal Investigator: Samuel A Smits, PhD         
Sponsors and Collaborators
January, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Samuel A. Smits, PhD January, Inc.

Layout table for additonal information
Responsible Party: January, Inc.
ClinicalTrials.gov Identifier: NCT03604250     History of Changes
Other Study ID Numbers: 2018-44
First Posted: July 27, 2018    Key Record Dates
Last Update Posted: December 3, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases